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Background and Aims: Hospital readmissions among COVID-19 patients have
increased the load on the healthcare systems and added more pressure to hospital
capacity. This affects the ability to accommodate newly diagnosed COVID-19
patients and other non-COVID-19 patients who require hospitalization. Therefore,
this systematic review aims to understand the rates of and risk factors for hospital
readmissions and all-cause mortality among COVID-19 patients who were hospital-
ized after being discharged following index hospitalization.
Methods: Our systematic review protocol is registered with the International
Prospective Register of Systematic Reviews (PROSPERO) (CRD42021232324) and
prepared in accordance with the Preferred Reporting Items for Systematic Reviews
and Meta-Analysis Protocols (PRISMA-P) 2015 statement. We will search MEDLINE
(Ovid), EMBASE (Ovid), MedRxiv, Web of Science (Science Citation Index), ProQuest
Coronavirus research database, Cochrane Covid-19 study register, and WHO
COVID-19: Global literature on coronavirus disease will be identified from December
31, 2019, to May 31, 2021. Two investigators will independently screen titles and
abstracts and select studies reporting hospital readmissions among COVID-19
patients. Further, data extraction and risk of bias assessment will be carried out sepa-
rately by these independent reviewers. We will extract data on demographics,
readmissions, all-cause mortality, emergency department visits, comorbidities, and
factors associated with hospitalization among COVID-19 patients. Random-effect
meta-analysis will be performed if homogeneous groups of studies are found. The
combined evidence will be further stratified according to important background char-
acteristics if the data allow.
Discussion: This systematic review will summarize the available epidemiological evi-
dence regarding rates of hospital readmissions, comorbidities, and related factors
among COVID-19 patients who were readmitted after index hospitalization. A better
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understanding of the relationship between patient profiles and the rate of hospitali-
zation will be helpful in the development of guidelines for patient management.
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1 | INTRODUCTION
As of September 7, 2021, the COVID-19 pandemic has resulted in
more than 222 million cases and 4.5 million deaths worldwide and
will continue to have far reaching impacts on healthcare systems
for many years.1 Most COVID-19 cases result in mild disease that
can be managed without hospitalization. However, if symptoms
are severe enough, along with other underlying medical conditions,
hospitalization is highly likely. Inpatient hospital readmissions due
to COVID-19 complications have been recorded but are not well
understood.2 Hospital readmission (or rehospitalization) among
COVID-19 patients is usually defined as the inpatient hospitaliza-
tion in a given follow-up time period (such as 30 or 60 days after
discharge) after discharge from index COVID-19 related
hospitalization.2-5
A post-covid syndrome has been identified and characterized
as a long-term effect with a broad range of new and existing medi-
cal conditions that are the result of COVID-19 infection.6 This cau-
ses complications to different organ systems, with the major ones
being the respiratory and cardiovascular systems, and ultimately
results in a specific or multiorgan dysfunction.2-6 For instance,
COVID-19 pneumonia has been shown to cause lung damage
reducing pulmonary function 4 months after acute infection.7
Inflammation from an acute infection can also cause micro-
angiopathic thrombosis, myocarditis, cardiac arrhythmias, heart
failure, and acute coronary syndrome.8 Other studies have also
reported that COVID-19 infection worsens the severity of existing
comorbidities resulting in an increased rate of readmission.2,5,6
The major chronic conditions reported are chronic kidney disease,
heart failure, and chronic obstructive pulmonary disease.5 Thus,
COVID-19 alters the normal physiological state of patients by new
conditions or existing comorbidities, which contribute to the sub-
sequent need for hospitalization.
The great majority of people infected with COVID-19 survive,
including those requiring hospital admission. Some patients who
are discharged after hospital admission are subsequently
readmitted, putting additional pressure on the availability of
hospital beds. There is limited systematic evidence available on
patient readmission after initial hospital discharge. Therefore,
specific questions to be answered in this systematic review are as
follows:
1. What are the rates of and risk factors for hospital readmission
(or inpatient hospitalization), and emergency department visits
among COVID-19 patients who were discharged after index
hospitalization?
2. What are the common comorbidities and other factors (demo-
graphic and clinical) associated with hospital readmission after a
patient's initial COVID-19 hospitalization and discharge?
3. What is the all-cause mortality rate among COVID-19 patients
who were hospitalized after being discharged following index
hospitalization?
2 | METHODS
Our systematic review protocol is registered with the International
Prospective Register of Systematic Reviews (PROSPERO)
(CRD42021232324). This protocol is prepared using the Preferred
Reporting Items for Systematic Reviews and Meta-Analysis Protocols
(PRISMA-P) 2015 statement.9 This systematic review will be prepared
and reported in compliance with the PRISMA 2020 statement.10
2.1 | Eligibility criteria
We will include all studies of patients with COVID-19, which report
readmissions to hospital after discharge from index hospitalization.
A hospital readmission can be defined as the inpatient hospitalization
in a given follow-up time period (such as 30- or 60-days after dis-
charge) after discharge from an index COVID-19 related hospitaliza-
tion.2-4 Studies reporting readmission after any follow-up time will be
included in this systematic review. We will include studies published
in all languages. We will exclude studies if multiple publications will be
identified using the same data. There are no additional exclusion
criteria. COVID-19 patients who were discharged but not readmitted
will be used as the comparator, if available, to calculate the risk of,
and factors associated with, hospital readmission.
2.2 | Study design
We will include quantitative studies of any design (eg, case series,
cross-sectional, case-control, and cohort studies). We will also include
any other studies that provide required quantitative information (such
as extended research letters, extended abstracts with required quanti-
tative details). We will exclude case reports and secondary research
such as reviews, systematic reviews, and evidence syntheses.
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However, we will check the reference list of these excluded articles
for any article fitting the inclusion criteria.
2.3 | Outcomes
2.3.1 | Primary outcome
• To estimate the rates of and risk factors for readmission among
COVID-19 patients who were discharged after index
hospitalization.
2.3.2 | Secondary outcomes
• To estimate the rate of emergency department visits among
COVID-19 patients who were discharged after index
hospitalization.
• To estimate mortality rates among COVID-19 patients who were
discharged after index hospitalization.
• To describe common comorbidities among COVID-19 patients
who were discharged after index hospitalization.
• To describe factors (demographic and clinical) associated with hos-
pital readmission after a patient's initial COVID-19 hospitalization.
2.4 | Search strategy
Search strategies have been developed and tested through an itera-
tive process with the help of an experienced medical information spe-
cialist. We will search MEDLINE (Ovid), EMBASE (Ovid), MedRxiv,
Web of Science (Science Citation Index), ProQuest Coronavirus
research database, Cochrane COVID-19 study register, and WHO
COVID-19: Global literature on coronavirus disease between
December 31, 2019 and May 31, 2021. We will also search eligible
studies through the following: (a) grey literature using Google scholar
and ResearchGate; and (b) checking reference lists of included studies.
A draft search strategy for MEDLINE is provided in Table S1.
2.5 | Study quality
The quality of included studies will be assessed by the National Insti-
tute of Health (NIH) quality assessment tools. The tools include items
for evaluating potential flaws in study methods or implementation,
including sources of bias (eg, patient selection, performance, attrition,
and detection), confounding, study power, the strength of causality in
the association between interventions and outcomes, and other fac-
tors.11 Reviewers can select “yes,” “no,” or “cannot determine/not
reported/not applicable” in response to each item on the tool. For
each item where “no” will be selected, reviewers are instructed to
consider the potential risk of bias that could be introduced by that
flaw in the study design or implementation. Cannot determine and
not reported will also be noted as representing potential flaws. Qual-
ity assessment will be carried out by two reviewers independently.
Discrepancies in quality appraisal scores will be resolved through
discussion or referred to a third reviewer.
2.6 | Data extraction
All search results will be downloaded from electronic databases and
imported into Rayyan, an online tool, for screening to remove dupli-
cates and data extraction.12 Two reviewers will independently screen
titles and abstracts against selection criteria and exclude irrelevant
studies by agreement. Review of full texts will be undertaken inde-
pendently by two reviewers to determine eligibility. Reasons for
rejecting papers at the full-text stage will be recorded. Any differences
of opinion regarding eligibility will be resolved through discussion or
by consulting with a third reviewer. Studies meeting inclusion criteria
will undergo data extraction by both reviewers and be independently
checked (randomly 25% of included studies) by a third reviewer for
accuracy and consistency. A standardized data extraction form will be
designed and piloted for collecting data for analysis. At the study
level, data will be extracted on the following:
• date of data extraction and data extractor
• study ID (author, year of publication)
• setting (country of origin)
• period of index hospitalization if available
• type of study
• funding sources
• age of participants (mean, SD, median, range, IQR)
• sex (counts and proportions)
• number of participants
• number of patients who were readmitted to hospital after dis-
charge from index hospitalization
• emergency department (ED) visits after discharge from index hos-
pitalization if reported
• number of patients who were died after discharge from index hos-
pitalization if reported
• details of comparator group, where relevant
• description of covariates where relevant (eg, demographic informa-
tion, comorbidities, type of readmission, length of hospital stay)
• measures of effect, where relevant
2.7 | Data synthesis
Readmission rate will be calculated as the ratio between the total
number of persons readmitted over the total patients who were dis-
charged after index hospitalization and will be presented as the
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number of cases per 100 population. Death rate and rate of ED visits
will also be calculated in a similar fashion. The reported proportions
will be presented with corresponding 95% confidence intervals (CIs)
using the exact binomial distribution.13 Meta-analysis of proportions
will be conducted if studies adequately meet the inclusion criterion
and are sufficiently uniform in reporting the outcome estimates.
Rates will be transformed on the double arcsine function in order to
avoid variance instability and CIs exceeding the interval (0 ≤ x ≤ 1) in
which proportions can be meaningfully defined. Risk of hospitaliza-
tion and factors associated with hospitalization will be reported as
risk ratios (RRs) with corresponding 95% CIs. A random-effects
model will be used to pool reported proportions. The residual or
restricted maximum likelihood method will be used to estimate τ2,
which produces an unbiased, non-negative estimate of between-
study variance. This is appropriate due to the methodological hetero-
geneity between studies.14 We will investigate potential sources of
heterogeneity related to both methodological and clinical character-
istics of the studies using Cochran's Q test (P < .1 considered signifi-
cant) and I2 (>50% representing moderate heterogeneity)
statistics.15 If meta-analysis is not feasible, results will be presented
narratively, and forest plots without pooling will be used to present
data. Publication bias will also be assessed using funnel plot asym-
metry and Egger's test for regression asymmetry (if we identify at
least 10 studies).16 We will use the “trim and fill” analysis of Duval
and Tweedie to examine the potential impact of missed or
unpublished studies on the pooled estimates of the rate of
readmission.17 Statistical analysis will be performed using Stata MP
v16.1 (StataCorp, College Station, Texas) and other open-source sta-
tistical software such as R v4.0.5 (R Foundation for Statistical Com-
puting, Vienna, Austria) and Review Manager v5.4 (the Nordic
Cochrane Centre, Rigshospitalet, Denmark).
2.8 | Subgroup analysis
If the number of studies allows, we will analyze by subgroup according
to age, sex, ethnicity, comorbidities, length of hospital stay, type of
readmission (example: 14, 30, and 60 days, etc), and geographic loca-
tion (eg, continent). Meta-regression technique will also be used to
explore association between certain factors (such as age, and gender)
and rate of readmission if adequate number of studies will be found
using the maximum likelihood method (P < .10 will be considered sig-
nificant given the low power of these tests).18
2.9 | Sensitivity analysis
Sensitivity analyses will be conducted by using influence and outlier
analyses to determine the effects of certain studies on the pooled
estimates of hospital readmissions.19 These analyses will assess how
the estimated parameter of a pooled analysis would change if noisy
studies were eliminated.
3 | DISCUSSION
The synthesis of the current literature for COVID-19 related
readmissions is vital in developing mechanisms to mitigate this costly
event. Several factors can play a role. The business model of different
hospitals and their quality of care should be assessed for any possible
associations with COVID-19 readmission. Moreover, the heteroge-
neous causes such as varying comorbidities in a COVID-19 patient
result in a complex, multifaceted source for readmission.6,20 Lastly,
despite COVID-19's presence for over a year, guidelines on post-
COVID-19 recovery have yet to be agreed upon worldwide, and hos-
pitals often have to employ new methods to deal with readmissions
among COVID-19 patients who initially hospitalized. Differing
healthcare settings across the world may impact on the quality of care
received by a patient. Essentially, most healthcare systems are divided
between public and private sectors. This factor is important as during
times of need, governments may call for a collaboration to enhance
capacity to combat pandemics and other health emergencies.
At the core, COVID-19's plethora of possible outcomes within a
patient imposes one of the largest contributing factors to patient
readmission. While many face relatively mild symptoms, unfortunately
for some, life support is necessary to maintain ventilation. Conse-
quently, a history of comorbidities such as diabetes, cardiovascular
disease, or other conditions leading to immunocompromise is associ-
ated with an increased risk of readmission. Some reasons have been
put forward. During the course of initial treatment, the use of intrave-
nous fluids, anticoagulants, and glucocorticoids resulted in negative
associations with COVID-19 patient readmissions.20 Furthermore,
when COVID-19 patients are compared against general patients of
similar personal backgrounds and clinical symptoms, they are still
associated with an increased risk of readmission and death.6 By study-
ing the factors associated with COVID-19 patients, we will explore
causes that may contribute to a greater risk of readmission.
There are no clear follow-up guidelines for COVID-19 patients
post-discharge and recovery. Instead, patients are managed on a case-
by-case basis relying on the given symptomatic conditions to then be
dealt with by a respective specialist in that field. Guidelines have now
been drafted for COVID-19 patients' initial admission,21,22 although
readmission guidelines are still lacking. This forces hospitals to employ
new methods to manage patients depending upon their model of care.
To alleviate this burden, this systematic review can help in formulating
the first step of developing international guidance for COVID-19
related readmissions.
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